Krane Funds Advisors LLC Acquires 4,191 Shares of Dr.Reddy’s Laboratories Ltd (RDY)

Share on StockTwits

Krane Funds Advisors LLC grew its holdings in Dr.Reddy’s Laboratories Ltd (NYSE:RDY) by 818.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,703 shares of the company’s stock after buying an additional 4,191 shares during the period. Krane Funds Advisors LLC’s holdings in Dr.Reddy’s Laboratories were worth $329,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the business. Commonwealth Bank of Australia grew its stake in shares of Dr.Reddy’s Laboratories by 1.4% in the 2nd quarter. Commonwealth Bank of Australia now owns 1,760,194 shares of the company’s stock worth $56,674,000 after buying an additional 24,262 shares in the last quarter. BlackRock Inc. grew its stake in shares of Dr.Reddy’s Laboratories by 10.9% in the 2nd quarter. BlackRock Inc. now owns 1,559,768 shares of the company’s stock worth $50,225,000 after buying an additional 153,920 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Dr.Reddy’s Laboratories by 20.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 835,827 shares of the company’s stock worth $26,930,000 after buying an additional 142,492 shares in the last quarter. Mondrian Investment Partners LTD lifted its holdings in shares of Dr.Reddy’s Laboratories by 112.7% in the 1st quarter. Mondrian Investment Partners LTD now owns 758,866 shares of the company’s stock worth $24,519,000 after acquiring an additional 402,080 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Dr.Reddy’s Laboratories by 3,398.8% in the 2nd quarter. Renaissance Technologies LLC now owns 573,810 shares of the company’s stock worth $18,477,000 after acquiring an additional 557,410 shares during the last quarter. 12.82% of the stock is owned by institutional investors and hedge funds.

RDY has been the subject of several analyst reports. ValuEngine lowered shares of Dr.Reddy’s Laboratories from a “hold” rating to a “sell” rating in a report on Monday, July 16th. Zacks Investment Research upgraded shares of Dr.Reddy’s Laboratories from a “hold” rating to a “strong-buy” rating and set a $37.00 target price for the company in a report on Friday, August 17th.

Dr.Reddy’s Laboratories stock opened at $35.87 on Thursday. The stock has a market capitalization of $5.83 billion, a PE ratio of 35.51 and a beta of 0.19. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.64 and a quick ratio of 1.19. Dr.Reddy’s Laboratories Ltd has a 12-month low of $28.13 and a 12-month high of $39.96.

Dr.Reddy’s Laboratories (NYSE:RDY) last released its earnings results on Thursday, July 26th. The company reported $0.40 earnings per share (EPS) for the quarter. The firm had revenue of $543.00 million during the quarter, compared to analyst estimates of $542.20 million. Dr.Reddy’s Laboratories had a net margin of 9.41% and a return on equity of 11.74%. research analysts forecast that Dr.Reddy’s Laboratories Ltd will post 1.35 EPS for the current year.

Dr.Reddy’s Laboratories Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Further Reading: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr.Reddy’s Laboratories Ltd (NYSE:RDY).

Institutional Ownership by Quarter for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply